The GOG Highlight Reel
Spring 2022
Thursday, June 9, 2022

A GOG Foundation, Inc. Educational Program
Larry J. Copeland, MD
The Ohio State University,
James Cancer Center &
President, The GOG Foundation, Inc.
LEARNING OBJECTIVES

Upon completion of the activities in this series, learners will demonstrate:

THE OVERALL OBJECTIVE FOR THIS SESSION IS TO SHOWCASE CLINICAL TRIALS AND OTHER NEWSWORTHY EDUCATION FROM MAJOR MEDICAL MEETINGS THROUGHOUT THE YEAR

Increased knowledge regarding
• The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
• The key trial data for newer therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
• The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers

Greater competence related to
• Selecting therapies and treatments for women with cervical, endometrial, and ovarian cancers

Greater confidence in their ability to:
• Counsel patients with cervical, endometrial, and ovarian cancers on new and cutting-edge therapies
GOG FACULTY DISCLOSURE INFORMATION

Virtual Symposium, “GOG Highlight Reel – Summer 2022”

June 2022
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company”* is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

<table>
<thead>
<tr>
<th>NAME: Speaker/Moderators</th>
<th>Individual’s Role(s) in Activity</th>
<th>Nothing To Disclose</th>
<th>DISCLOSURE&lt;company &amp; role&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Coleman, MD</td>
<td>Planning/Speaker</td>
<td></td>
<td>Honorarium: Abbvie, Agenus, Alkermes, AstraZeneca, Clovis, Epsilogen, Genmab/Seattle Genetics, Gradalis, GSK, Immunogen, Janssen, Myriad, Novocure, Oncoquest, Oncoligie, Roche/Genentech</td>
</tr>
<tr>
<td>Angeles Alvarez Secord, MD</td>
<td>Advisory Board: Myriad Contracted clinical trial research: AbbVie, AstraZeneca, Boehringer, Clovis, Easai, Immutep. Ltd, Merck, National Cancer Trial Network, Oncoquest, PharmaMar, Roche/Genentech, Seagen inc., Tesaro/GSK, VBL Therapeutics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramez Eskander, MD</td>
<td>Advisory Board/Consulting Fee/Speaking: AstraZeneca; Merck; GSK; Myriad</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas Herzog, MD</td>
<td>Speaker</td>
<td></td>
<td>Advisory board: AstraZeneca, Aravive, Blueprint, Alkermes, OnxXema, Easai, GSK, Elevar, Genentech, Immunogen, Merck, VBL, Mersana, Myriad</td>
</tr>
<tr>
<td>Kathleen Moore, MD</td>
<td>Speaker</td>
<td></td>
<td>Honororium: Roche Diagnostics, Watermark, Immunogen, AstraZeneca, Sorrento, Rubius, Elevar, Novartis, Easai, GSK, Novocure, Genentech, GO Foundation, Mersana, Seattle Genetics, Ambray, Regeneron, Myriad, GSK/Tesaro, Agenus</td>
</tr>
<tr>
<td>David O’Malley, MD</td>
<td>Speaker</td>
<td>Advisory Board: GSK, Myriad</td>
<td></td>
</tr>
<tr>
<td>Bhavana Pothuri, MD</td>
<td>Speaker</td>
<td>Research funding support/Ad Board fees: AstraZeneca, Celsion ,Immunogen, Merck, Mersana,Seattle Genetics, Sutro, Takada, Tesaro, Clovis Oncology</td>
<td></td>
</tr>
<tr>
<td>Leslie Randall, MD</td>
<td>Speaker</td>
<td>Consulting fee: Agenus, Clovis, Myriad, Mersana, GSK/Tesaro Research Grant/ Contractor: Merck, Pfizer</td>
<td></td>
</tr>
<tr>
<td>Brian Slomovitz, MD</td>
<td>Speaker</td>
<td>Consultant: Abbvie, AstraZeneca, Clovis, GSK, Genentech, Merck, Myriad</td>
<td></td>
</tr>
<tr>
<td>Michelle Small</td>
<td>Staff</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jill Reese</td>
<td>Staff</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
COMMERCIAL SUPPORTERS

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium.
MODERATORS

Bradley J. Monk, MD
Bradley Monk, MD, Director, Principal Investigator, Community Research Development, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph’s, Hospital Phoenix, Arizona, USA

Robert Coleman, MD
US Oncology, Houston, Texas, USA
FACULTY

- Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA
- Leslie Randall, MD, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
- David O’Malley, MD, The Ohio State University, Columbus, Ohio, USA
- Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
- Ramez Eskander, MD, UC San Diego, San Diego, California, USA
- Angeles Alvarez Secord, MD, Duke University, Durham, North Carolina, USA
- Bhavana Pothuri, MD, NYU Langone, New York City, New York, USA
- Thomas J. Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA
AGENDA

2:30 pm – 2:40 pm  Welcome & Introduction
Larry J. Copeland, MD, The Ohio State, James Cancer Center & President, The GOG Foundation, Inc
Bradley Monk, MD, Director, Principal Investigator, Community Research Development, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph’s Hospital Phoenix, Arizona, USA
Robert Coleman, MD, US Oncology, Houston, Texas, USA

2:40 pm – 2:55 pm  Uterine Highlights from Spring Gynecologic Meetings
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA

2:55 pm – 3:10 pm  Uterine Panel Discussion
All Faculty

3:10 pm – 3:30 pm  Cervical Highlights from Spring Gynecologic Meetings
Leslie Randall, MD, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA

3:30 pm – 3:50 pm  Cervical Panel Discussion
All Faculty
AGENDA

3:50 pm – 4:00 pm  Ovarian Highlights: Frontline Sensitive from Spring Gynecologic Meetings
                    David O’Malley, MD, The Ohio State University, Columbus, Ohio, USA

4:00 pm – 4:15 pm  Ovarian Discussion: Frontline Sensitive
                    All Faculty

4:15 pm – 4:25 pm  Ovarian Highlights: PROC from Spring Gynecologic Meetings
                    Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA

4:25 pm – 4:40 pm  Ovarian Panel Discussion: PROC
                    All Faculty

4:40 pm – 5:00 pm  GOG Partners, Trials in Progress
                    All Faculty

5:00 pm - 5:30 pm  The Final Word
                    All Faculty
THANK YOU

GO TO WWW.GOG.ORG to view this presentation through November 11, 2022
Currently what is your biggest barrier to clinical trial enrollment?

1. No trials open
2. Staff shortage
3. Competing trials
4. Reimbursement
5. Other
1. No trials open
2. Staff shortage
3. Competing trials
4. Reimbursement
5. Other